Last reviewed · How we verify
Teridax (iophenoic acid)
Teridax (generic name: iophenoic acid) is a iophenoic acid drug. It is currently in unknown development.
Teridax works by interacting with a specific cellular target to produce its therapeutic effect.
Teridax, also known as iophenoic acid, is a small molecule drug of the iophenoic acid class. Its target and exact mechanism of action are unknown. It is not FDA-approved for any indications. The commercial status of Teridax is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety and efficacy.
At a glance
| Generic name | iophenoic acid |
|---|---|
| Drug class | iophenoic acid |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of it like a key fitting into a lock. Teridax is the key, and it fits into a specific lock on the cell, allowing it to send a signal that helps to treat a particular condition. However, the exact details of how it works are still not fully understood.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teridax CI brief — competitive landscape report
- Teridax updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Teridax
What is Teridax?
How does Teridax work?
What is the generic name of Teridax?
What drug class is Teridax in?
What development phase is Teridax in?
Related
- Drug class: All iophenoic acid drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing